DOJOLVI generic entry is deferred to 2033, but one patent fight ends

The market already knew generic challengers were pursuing DOJOLVI. Ultragenyx had disclosed ANDA litigation involving Esjay and other filers, so the existence of a legal overhang was not new. Public filings identify DOJOLVI’s key patent protection as extending into 2034, while orphan-drug exclusivity runs only through June 30, 2027.

The settlement largely preserves near-term exclusivity, but gives up roughly a year versus the stated patent horizon. Esjay may launch its generic on January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted (Settlement terms). That is far later than the June 30, 2027 orphan-exclusivity date and removes the risk of an immediate adverse court ruling against this specific challenger, but it is earlier than the 2034 patent expiration referenced in the company’s filings. The agreement is also royalty-free, so the filing discloses no offsetting settlement revenue (Settlement terms).

The net read is mixed rather than clearly positive. There is no reliable published consensus for the outcome of this patent case. Relative to a favorable litigation outcome, a 2033 launch is a modest concession; relative to the risk that Esjay could win earlier, it is protective. Because other DOJOLVI ANDA lawsuits remain pending, this resolves only one challenger and does not eliminate the broader generic-entry uncertainty (Other Events). DOJOLVI generated $96 million in 2025 and Ultragenyx guided to $100 million-$110 million for 2026, making the asset meaningful but not the company’s largest revenue driver.